



***HCV – new drugs, new chances and challenges
in treatment and diagnostics***

December 8, 2011

***University Hospital Zurich
Rämistrasse 100, 8091 Zürich***

Hörsaal West, 14h-19h

Dear colleagues,

The new drugs for the treatment of Hepatitis C Virus infection will bring new chances but also challenges for treatment and diagnostics. To obtain an update on evolving new drugs against HCV, their resistance patterns and the ensuing consequences for treatment and diagnostics we will hold a Mini-Symposium on Dec 8, 2011 at the University Hospital Zurich. The program and further details on the symposium can be downloaded from our website http://www.virology.uzh.ch/newsd_en.html.

We hope you find this topic interesting and look forward to see you in December

Sincerely,

Alexandra Trkola

On behalf of the program committee

Program committee

Alexandra Trkola	Institute of Medical Virology, University of Zurich
Huldrych Günthard	Division of Infectious Diseases, University Hospital Zurich
Jürg Böni	Institute of Medical Virology, University of Zurich
Andri Rauch	Division of Infectious Diseases, Inselspital Bern
Beat Müllhaupt	Division of Gastroenterology and Hepatology, University Hospital Zurich



HCV – new drugs, new chances and challenges in treatment and diagnostics

December 8, 2011

University Hospital Zurich

Rämistrasse 100, 8091 Zürich

Hörsaal West, 14h-19h

- Admission:** There is no admission fee.
- Registration:** Registration is required. Please send an email to wiget.monika@virology.uzh.ch to register for the symposium.
- Lodging and travel:** We kindly ask participants to organize travel and accommodation individually.
- Credits:** This symposium is recognized with 4 CME credits by the FAMH, Microbiology, the Swiss Society of Gastroenterology and the Swiss Society of Infectious Diseases.

Stefan Zeuzem	Johann Wolfgang Goethe-Universität, Frankfurt	New HCV therapies
David Wyles	University of California, San Diego	New drugs and resistance
Karin Metzner	University Hospital Zurich	Resistance testing: Lessons from HIV, Options for HCV
Stephane Chevaliez	Université Paris-Est Créteil	How to use virological tools for the optimal management of chronic hepatitis C
Markus Heim	Universität Basel	The future of interferon therapy

We gratefully acknowledge the main sponsors of this symposium,

Roche Diagnostics (Schweiz) AG
 Roche Pharma (Schweiz) AG
 Merck Sharp&Dohme-Cibret AG
 Janssen-Cilag AG



MSD



and a generous contribution by Abbott AG

